DOCSLIB.ORG

Active SMAC List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Active SMAC List West Virginia Medicaid State Maximum Allowable Cost (SMAC) List Effective 7/30/2021 Disclaimer: Price listing does not guarantee coverage Generic Name Prev. SMAC Price Prev. Effective Current SMAC Current Effective Date Price Date 0.9 % SODIUM CHLORIDE INJECTION VIAL (ML) 0.9 % 0.05712 08/12/2014 0.9 % SODIUM CHLORIDE INTRAVENOUS INTRAVENOUS SOLUTION 0.9 0.00196 03/06/2015 0.00196 08/21/2015 % 0.9 % SODIUM CHLORIDE INTRAVENOUS PIGGYBACK WITH THREADED 0.03505 01/30/2015 0.03505 08/21/2015 PORT (ML) 0.9 % SODIUM CHLORIDE INTRAVENOUS PIGGYBACK WITH VIAL PORT 0.04175 07/18/2014 (NON-THREADED) ABACAVIR SULFATE ORAL TABLET 300 MG 1.77633 11/25/2017 0.36867 05/22/2020 ABIRATERONE ACETATE ORAL TABLET 250 MG 3.78000 02/21/2020 4.56040 02/24/2020 ACAMPROSATE CALCIUM ORAL TABLET, DELAYED RELEASE (ENTERIC 0.74145 04/09/2020 0.70192 06/19/2020 COATED) 333 MG ACARBOSE ORAL TABLET 100 MG 0.18990 03/02/2018 0.13000 11/16/2018 ACARBOSE ORAL TABLET 25 MG 0.23329 08/21/2015 0.13994 08/25/2017 ACARBOSE ORAL TABLET 50 MG 0.14640 05/25/2018 0.12500 11/16/2018 ACEBUTOLOL HCL ORAL CAPSULE 200 MG 0.60776 10/07/2019 0.55890 06/18/2021 ACEBUTOLOL HCL ORAL CAPSULE 400 MG 0.26000 08/21/2015 0.68650 05/11/2021 ACETAMINOPHEN ORAL CAPSULE 500 MG 0.01093 08/12/2014 ACETAMINOPHEN ORAL DROPS 80MG/0.8ML 0.17160 10/11/2013 0.17160 08/21/2015 ACETAMINOPHEN ORAL LIQUID (ML) 160 MG/5ML 0.00932 09/27/2013 0.00932 08/21/2015 ACETAMINOPHEN ORAL SUSPENSION, ORAL (FINAL DOSE FORM) 160 0.02137 08/21/2015 0.02033 02/17/2017 MG/5ML ACETAMINOPHEN ORAL SUSPENSION, ORAL (FINAL DOSE FORM) 160 0.01083 06/09/2017 0.02033 03/02/2018 MG/5ML ACETAMINOPHEN ORAL TABLET 325 MG 0.00830 06/20/2014 0.00830 08/21/2015 ACETAMINOPHEN ORAL TABLET 500 MG 0.01040 04/03/2015 0.01040 08/21/2015 ACETAMINOPHEN ORAL TABLET,CHEWABLE 80 MG 0.04651 04/03/2015 0.04651 08/21/2015 ACETAMINOPHEN ORAL TABLET,DISINTEGRATING 80 MG 0.05113 08/21/2015 ACETAMINOPHEN RECTAL SUPPOSITORY, RECTAL 120 MG 0.20324 08/22/2014 0.20324 08/21/2015 ACETAMINOPHEN RECTAL SUPPOSITORY, RECTAL 325 MG 0.46400 08/22/2014 0.46400 08/21/2015 ACETAMINOPHEN RECTAL SUPPOSITORY, RECTAL 650 MG 0.21762 08/22/2014 0.21762 08/21/2015 ACETAMINOPHEN WITH CODEINE PHOSPHATE ORAL SOLUTION, ORAL 0.01332 01/30/2015 0.01332 08/21/2015 120-12MG/5 ACETAMINOPHEN WITH CODEINE PHOSPHATE ORAL SOLUTION, ORAL 0.21394 03/27/2015 0.21394 08/21/2015 120-12MG/5 ACETAMINOPHEN WITH CODEINE PHOSPHATE ORAL SOLUTION, ORAL 0.10079 03/27/2015 0.10079 08/21/2015 300MG/12.5 ACETAMINOPHEN WITH CODEINE PHOSPHATE ORAL TABLET 300MG- 0.14344 09/19/2014 0.14344 08/21/2015 15MG ACETAMINOPHEN WITH CODEINE PHOSPHATE ORAL TABLET 300MG- 0.10480 10/20/2017 0.09167 12/22/2017 30MG ACETAMINOPHEN WITH CODEINE PHOSPHATE ORAL TABLET 300MG- 0.19101 05/20/2016 0.17150 08/17/2018 60MG ACETAMINOPHEN/DIPHENHYDRAMINE HCL ORAL TABLET 500MG-25MG 0.04047 04/24/2015 0.04047 08/21/2015 ACETAZOLAMIDE ORAL CAPSULE, EXTENDED RELEASE 500 MG 0.94140 09/22/2017 0.70000 11/16/2018 ACETAZOLAMIDE ORAL TABLET 125 MG 1.29790 11/16/2018 0.53466 05/21/2021 ACETAZOLAMIDE ORAL TABLET 250 MG 0.68040 09/25/2020 0.57850 12/25/2020 ACETIC ACID IRRIGATION SOLUTION, IRRIGATION 0.25 % 0.00350 03/01/2013 ACETIC ACID OTIC SOLUTION, NON-ORAL 2 % 1.65333 02/21/2020 1.38600 09/25/2020 West Virginia Medicaid State Maximum Allowable Cost (SMAC) List Effective 7/30/2021 Disclaimer: Price listing does not guarantee coverage Generic Name Prev. SMAC Price Prev. Effective Current SMAC Current Effective Date Price Date ACETIC ACID/ALUMINUM ACETATE DROPS 2 % 0.84000 01/25/2013 0.84000 08/21/2015 ACETYLCYSTEINE INTRAVENOUS VIAL (ML) 200 MG/ML 5.26400 03/06/2015 5.26400 08/21/2015 ACETYLCYSTEINE MISCELLANEOUS VIAL (ML) 100 MG/ML 0.45068 08/21/2015 0.35144 02/21/2020 ACETYLCYSTEINE MISCELLANEOUS VIAL (ML) 200 MG/ML 0.34100 03/27/2020 0.32978 08/28/2020 ACETYLCYSTEINE/MECOBALAMIN/LEVOMEFOLATE CALCIUM ORAL 1.89794 02/20/2015 1.89794 08/21/2015 TABLET 600-2-6 MG ACITRETIN ORAL CAPSULE 10 MG 9.53166 12/18/2017 6.66000 06/18/2021 ACITRETIN ORAL CAPSULE 17.5 MG 42.31920 03/21/2014 ACITRETIN ORAL CAPSULE 25 MG 9.33333 05/17/2019 6.57371 06/18/2021 ACYCLOVIR ORAL CAPSULE 200 MG 0.08844 08/21/2015 0.05480 09/22/2017 ACYCLOVIR ORAL SUSPENSION, ORAL (FINAL DOSE FORM) 200 MG/5ML 0.40698 01/19/2020 0.39070 08/28/2020 ACYCLOVIR ORAL TABLET 400 MG 0.06655 07/14/2017 0.05351 11/16/2018 ACYCLOVIR ORAL TABLET 800 MG 0.13520 12/22/2017 0.11600 08/16/2019 ACYCLOVIR SODIUM INTRAVENOUS VIAL (EA) 500 MG 31.20600 08/22/2014 31.20600 08/21/2015 ACYCLOVIR SODIUM INTRAVENOUS VIAL (ML) 50 MG/ML 1.40750 07/25/2014 ACYCLOVIR TOPICAL OINTMENT (GRAM) 5 % 1.94109 11/15/2019 0.89933 05/22/2020 ADAPALENE TOPICAL CREAM (GRAM) 0.1 % 3.31978 12/25/2020 3.31978 01/01/2021 ADAPALENE TOPICAL GEL (GRAM) 0.1 % 1.58578 11/15/2019 1.58578 01/01/2021 ADAPALENE TOPICAL GEL (GRAM) 0.3 % 3.41117 06/16/2017 3.41117 01/01/2021 ADAPALENE TOPICAL GEL WITH PUMP (GRAM) 0.3 % 4.61985 08/21/2015 4.61985 01/01/2021 ADEFOVIR DIPIVOXIL ORAL TABLET 10 MG 26.52627 09/27/2013 ALBUMIN HUMAN INTRAVENOUS INTRAVENOUS SOLUTION 25 % 1.51200 05/01/2015 1.51200 08/21/2015 ALBUMIN HUMAN INTRAVENOUS INTRAVENOUS SOLUTION 5 % 0.21588 09/19/2014 0.21588 08/21/2015 ALBUTEROL SULFATE INHALATION SOLUTION, NON-ORAL 5 MG/ML 1.45230 10/23/2017 2.12250 12/27/2019 ALBUTEROL SULFATE INHALATION VIAL, NEBULIZER (EA) 2.5 MG/0.5 0.43876 08/01/2014 ALBUTEROL SULFATE INHALATION VIAL, NEBULIZER (ML) 0.63MG/3ML 0.15441 11/16/2018 0.11333 11/15/2019 ALBUTEROL SULFATE INHALATION VIAL, NEBULIZER (ML) 1.25MG/3ML 0.19073 06/21/2019 0.15240 12/20/2019 ALBUTEROL SULFATE INHALATION VIAL, NEBULIZER (ML) 2.5 MG/3ML 0.05253 08/21/2015 0.03400 01/19/2018 ALBUTEROL SULFATE ORAL SYRUP 2 MG/5 ML 0.01277 08/21/2015 0.03571 08/28/2019 ALBUTEROL SULFATE ORAL TABLET 2 MG 4.56651 08/21/2015 4.05000 12/25/2015 ALBUTEROL SULFATE ORAL TABLET 4 MG 3.62765 12/25/2015 2.00000 06/18/2021 ALBUTEROL SULFATE ORAL TABLET, EXTENDED RELEASE 12 HR 4 MG 1.18451 04/25/2014 ALBUTEROL SULFATE ORAL TABLET, EXTENDED RELEASE 12 HR 8 MG 1.71821 04/05/2013 ALCLOMETASONE DIPROPIONATE TOPICAL CREAM (GRAM) 0.05 % 0.88300 08/16/2019 0.62717 03/20/2020 ALCLOMETASONE DIPROPIONATE TOPICAL OINTMENT (GRAM) 0.05 % 0.58692 06/28/2013 ALENDRONATE SODIUM ORAL SOLUTION, ORAL 70 MG/75ML 2.45700 09/27/2013 ALENDRONATE SODIUM ORAL TABLET 10 MG 0.18750 08/21/2015 0.13200 10/20/2017 ALENDRONATE SODIUM ORAL TABLET 35 MG 0.35333 08/17/2018 0.23750 05/17/2019 ALENDRONATE SODIUM ORAL TABLET 40 MG 2.80060 03/27/2015 ALENDRONATE SODIUM ORAL TABLET 5 MG 0.18110 08/12/2014 0.18110 08/21/2015 ALENDRONATE SODIUM ORAL TABLET 70 MG 0.23250 09/21/2018 0.20500 12/25/2020 ALFUZOSIN HCL ORAL TABLET, EXTENDED RELEASE 24 HR 10 MG 0.11326 03/16/2018 0.05870 05/22/2020 West Virginia Medicaid State Maximum Allowable Cost (SMAC) List Effective 7/30/2021 Disclaimer: Price listing does not guarantee coverage Generic Name Prev. SMAC Price Prev. Effective Current SMAC Current Effective Date Price Date ALLOPURINOL ORAL TABLET 100 MG 0.07267 11/16/2018 0.04709 01/25/2019 ALLOPURINOL ORAL TABLET 300 MG 0.09110 07/26/2019 0.05230 07/17/2020 ALMOTRIPTAN MALATE ORAL TABLET 12.5 MG 25.31000 08/25/2017 16.33370 10/19/2018 ALPHA LIPOIC ACID ORAL CAPSULE 200 MG 0.12771 08/08/2014 0.12771 08/21/2015 ALPHA LIPOIC ACID ORAL CAPSULE 50 MG 0.10210 08/12/2014 0.10210 08/21/2015 ALPRAZOLAM ORAL TABLET 0.25 MG 0.01509 05/16/2014 0.01509 08/21/2015 ALPRAZOLAM ORAL TABLET 0.5 MG 0.01780 08/21/2015 0.01462 03/19/2021 ALPRAZOLAM ORAL TABLET 1 MG 0.01970 02/06/2015 0.01970 08/21/2015 ALPRAZOLAM ORAL TABLET 2 MG 0.07213 09/28/2015 0.04891 12/22/2017 ALPRAZOLAM ORAL TABLET, EXTENDED RELEASE 24 HR 0.5 MG 0.36136 08/21/2015 0.18083 09/22/2017 ALPRAZOLAM ORAL TABLET, EXTENDED RELEASE 24 HR 1 MG 0.21717 09/22/2017 0.16917 03/19/2021 ALPRAZOLAM ORAL TABLET, EXTENDED RELEASE 24 HR 2 MG 0.40200 08/17/2018 0.37733 01/15/2021 ALPRAZOLAM ORAL TABLET, EXTENDED RELEASE 24 HR 3 MG 0.55483 11/20/2015 0.35500 09/22/2017 ALPRAZOLAM ORAL TABLET,DISINTEGRATING 0.25 MG 1.36123 03/01/2013 1.36123 08/21/2015 ALPRAZOLAM ORAL TABLET,DISINTEGRATING 0.5 MG 1.51669 01/25/2013 1.51669 08/21/2015 ALPRAZOLAM ORAL TABLET,DISINTEGRATING 1 MG 2.02358 01/25/2013 2.02358 08/21/2015 ALPRAZOLAM ORAL TABLET,DISINTEGRATING 2 MG 3.00202 01/25/2013 3.00202 08/21/2015 ALUMINUM HYDROXIDE ORAL SUSPENSION, ORAL (FINAL DOSE FORM) 0.00813 08/21/2015 320 MG/5ML AMANTADINE HCL ORAL CAPSULE 100 MG 0.24644 08/17/2018 0.18726 12/25/2020 AMANTADINE HCL ORAL SOLUTION, ORAL 50 MG/5 ML 0.01733 04/03/2015 0.01733 08/21/2015 AMANTADINE HCL ORAL TABLET 100 MG 0.13100 08/16/2019 0.43980 06/09/2020 AMBRISENTAN ORAL TABLET 10 MG 38.40000 02/21/2020 AMBRISENTAN ORAL TABLET 5 MG 38.40000 02/21/2020 AMCINONIDE TOPICAL CREAM (GRAM) 0.1 % 2.82140 08/12/2014 AMCINONIDE TOPICAL LOTION (ML) 0.1 % 1.90000 08/12/2014 AMCINONIDE TOPICAL OINTMENT (GRAM) 0.1 % 4.53600 08/30/2013 AMIKACIN SULFATE INJECTION VIAL (ML) 1000MG/4ML 3.14373 12/05/2014 3.14373 08/21/2015 AMIKACIN SULFATE INJECTION VIAL (ML) 500 MG/2ML 2.95555 12/05/2014 2.95555 08/21/2015 AMILORIDE HCL ORAL TABLET 5 MG 0.14880 11/15/2019 0.13230 05/22/2020 AMILORIDE HCL/HYDROCHLOROTHIAZIDE ORAL TABLET 5 MG-50 MG 0.42250 05/30/2014 0.42250 08/21/2015 AMINO ACIDS ORAL POWDER (GRAM) 0.25540 08/12/2014 AMINOCAPROIC ACID INTRAVENOUS VIAL (ML) 250 MG/ML 0.08148 02/06/2015 0.08148 08/21/2015 AMINOCAPROIC ACID ORAL TABLET 1000 MG 18.30610 08/12/2014 18.30610 08/21/2015 AMINOCAPROIC ACID ORAL TABLET 500 MG 5.37896 10/11/2013 5.37896 08/21/2015 AMINOPHYLLINE INTRAVENOUS VIAL (ML) 250MG/10ML 0.30912 01/30/2015 0.30912 08/21/2015 AMINOPHYLLINE INTRAVENOUS VIAL (ML) 500MG/20ML 0.07270 08/12/2014 AMIODARONE HCL INTRAVENOUS AMPUL (ML) 50 MG/ML 0.33600 01/25/2013 AMIODARONE HCL ORAL TABLET 100 MG 1.97100 03/20/2020 1.39967 10/23/2020 AMIODARONE HCL ORAL TABLET 200 MG 0.12724 09/30/2016 0.09890 11/16/2018 AMIODARONE HCL ORAL TABLET 400 MG 3.19526 08/22/2014 2.81936 12/02/2016 AMITRIPTYLINE HCL ORAL TABLET 10 MG 0.05742 11/16/2018 0.03550 08/16/2019 West Virginia Medicaid State Maximum Allowable Cost (SMAC) List Effective 7/30/2021 Disclaimer: Price listing does not guarantee coverage Generic Name Prev.
Load more

Recommended publications
  • VOLUME 7 2 . No. 4 . AUGUST 2 0
    VOLUME 72 . No.4 . AUGUST 2020 © 2020 EDIZIONI MINERVA MEDICA Minerva Pediatrica 2020 August;72(4):288-311 Online version at http://www.minervamedica.it DOI: 10.23736/S0026-4946.20.05861-2 REVIEW MANAGEMENT OF THE MAIN ENDOCRINE AND DIABETIC DISORDERS IN CHILDREN Current treatment for polycystic ovary syndrome: focus on adolescence Maria E. STREET 1 *, Francesca CIRILLO 1, Cecilia CATELLANI 1, 2, Marco DAURIZ 3, 4, Pietro LAZZERONI 1, Chiara SARTORI 1, Paolo MOGHETTI 4 1Division of Pediatric Endocrinology and Diabetology, Department of Mother and Child, Azienda USL – IRCCS di Reggio Emilia, Reggio Emilia, Italy; 2Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy; 3Section of Endocrinology and Diabetes, Department of Internal Medicine, Bolzano General Hospital, Bolzano, Italy; 4Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Hospital Trust of Verona, Verona, Italy *Corresponding author: Maria E. Street, Division of Pediatric Endocrinology and Diabetology, Department of Mother and Child, Azienda USL – IRCCS di Reggio Emilia, Viale Risorgimento 80, 42123 Reggio Emilia, Italy. E-mail: [email protected] ABSTRACT Polycystic ovary syndrome (PCOS) is the most frequent endocrine disorder in women and it is associated with an in- creased rate of infertility. Its etiology remains largely unknown, although both genetic and environmental factors play a role. PCOS is characterized by insulin resistance, metabolic disorders and low-grade chronic inflammation. To date, the treatment of PCOS is mainly symptomatic and aimed at reducing clinical signs of hyperandrogenism (hirsutism and acne), at improving menstrual cyclicity and at favoring ovulation. Since PCOS pathophysiology is still largely unknown, the therapeutic interventions currently in place are rarely cause-specific.
    [Show full text]
  • Purified Sea Salt with Magnesium Carbonate
    Cargill® Food Processing Salts Purified Sea Saltwith Magnesium Carbonate Product Description Physical Information Purified Sea Salt with Magnesium Carbonate This material is a food grade, granular, white crystalline Purified Sea Salt with Magnesium Carbonate sodium chloride product manufactured under stringent PHYSICAL MIN TARGET MAX process control procedures. Cargill Sea Salts are made from Pacific Ocean sea salt, which is harvested from ponds NaCl (%) 99.7 99.96 100 near the San Francisco Bay. Ca & Mg as Ca (%) 0.003 Sulfate as SO4 (%) 0.01 Product Application Water Insolubles (%) 0.025 0.01 Bulk Density (#cu/ft) 69 74 84 This material is intended for table and cooking use, as well as direct application in foods manufactured by the various Bulk Density (g/l) 1105 1185 1345 food processing industries. This material contains Surface Moisture (%) 0.02 Magnesium Carbonate, which is added to improve caking Magnesium Carbonate (%) 0.5 resistance and flowability. PERCENT PARTICLE SIZE MIN TARGET MAX Product Certifications DISTRIBUTION (SCREENS) Sieve - USS 30 Mesh Retained 0 40 50 Cargill® Sea Salts meet USDA, FDA and Food Chemicals Codex for food use. Sieve - USS 40 Mesh Retained 34 Sieve - USS 50 Mesh Retained 16 Cargill® Sea Salts are certified Kosher for Passover (OU-P) SieveCargill - USS 70 Mesh® RetainedSea Salt 8 by the Orthodox Union. Sieve - Retained on Pan 0 1 10 Made with Sun, Wind and Time Allergen Status Harvesting sea salt from San Francisco Bay today is similar to the salt-making process that has been used for centuries. In accordance with the 2004 USA Food Allergen Labeling and Consumer Protection Act (FALCPA), no allergen declarations are required for this product.
    [Show full text]
  • An Open-Label Pilot Trial of Alpha-Lipoic Acid for Weight Loss in Patients with Schizophrenia Without Diabetes Joseph C
    Case Reports An Open-Label Pilot Trial of Alpha-Lipoic Acid for Weight Loss in Patients with Schizophrenia without Diabetes Joseph C. Ratliff1 , Laura B. Palmese 1, Erin L. Reutenauer 1, Cenk Tek 1 Abstract A possible mechanism of antipsychotic-induced weight gain is activation of hypothalamic monophosphate-dependent kinase (AMPK) mediated by histamine 1 receptors. Alpha-lipoic acid (ALA), a potent antioxidant, counteracts this ef- fect and may be helpful in reducing weight for patients taking antipsychotics. The objective of this open-label study was to assess the efficacy of ALA (1,200 mg) on twelve non-diabetic schizophrenia patients over ten weeks. Participants lost significant weight during the intervention (-2.2 kg±2.5 kg). ALA was well tolerated and was particularly effective for individuals taking strongly antihistaminic antipsychotics (-2.9 kg±2.6 kg vs. -0.5 kg±1.0 kg). Clinical Trial Registra- tion: NCT01355952. Key Words: Schizophrenia, Obesity, Schizoaffective Disorder, Alpha-Lipoic Acid Introduction dependent protein kinase (AMPK) in the hypothalamus Antipsychotic medications appear to induce weight (4). In the periphery, AMPK increases energy utilization; gain, which results in increased rates of obesity in schizo- AMPK activity in the hypothalamus increases appetite. phrenia (1). Schizophrenia patients have significantly short- Several highly orexigenic (stimulates appetite) antipsy- er life expectancy than the general population (2); most of chotics such as clozapine, olanzapine, and quetiapine are this excess mortality is attributed to diabetes and cardiovas- shown to activate AMPK in the hypothalamus in animal cular disease (3); weight gain is a significant contributor to studies whereas other antipsychotic medications do not (4).
    [Show full text]
  • Medication Other Information Aches and Pains Constipation Cough/Cold Diarrhea Fever Over the Counter Medications in Pregnancy
    Over the Counter Medications in Pregnancy Women commonly use over the counter medications in pregnancy. This is a list of those medication you may safely use during pregnancy. If you have any questions about these medications and how to use them please contact your Healthcare Provider's office. Unless otherwise stated please take the medication as directed on the manufactures label. Medication Other Information Aches and Pains * Tylenol Extra Strength 500 mg tablet No more than 6 tablets in a 24 hour period * Tylenol 325 mg tablet No more than 8 in a 24 hour period Constipation Stool Softener Increases the amount of water in your stools to make them easier to pass * Colace (docusate sodium) * Surfak (docusate calcium) * Docusate Fiber Laxative Increases the amount of bulk in your stools to make them easier to pass * Metamucil (psyllium) * Fibercon (Calcium polycarbophil 625 mg) Stool Softener/Fiber Laxative Increases the amount of water in your stools to make them easier to pass * Peri-Colace (docusate sodium/sennosides) * Senekot -S (docusate sodium/sennosides) Osmotic Laxative Increases the amount of water in your stools to make them easier to pass * Milk of Magnesia * MiraLax (polyethylene glycol 3350) Cough/Cold Expectorants Help thin mucus and phlegm so they can be coughed up * Robitussin * Guaifenesin Antihistamines Can be used to relieve seasonal allergy and common cold symptoms of nasal congestion, * Chlorpheniramine sneezing and itchy eyes Cough Suppressants Help calm a cough * Dextromethorphan Decongestants Are used to relieve
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0236506 A1 SCHWARTZ Et Al
    US 2011 0236506A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0236506 A1 SCHWARTZ et al. (43) Pub. Date: Sep. 29, 2011 (54) PHARMACEUTICAL ASSOCIATION Publication Classification CONTAINING LIPOCACID AND (51) Int. Cl. HYDROXYCTRIC ACIDAS ACTIVE A633/24 (2006.01) INGREDIENTS A63L/385 (2006.01) A63/685 (2006.01) (75) Inventors: Laurent SCHWARTZ, Paris (FR): A63/4985 (2006.01) Adeline GUAIS-VERGNE, A63L/7056 (2006.01) Draveil (FR) A6IP35/00 (2006.01) (73) Assignees: Laurent SCHWARTZ, Paris (FR): (52) U.S. Cl. ........... 424/649; 514/440; 514/77: 514/249; BIOREBUS, Paris (FR) 514/52 (21) Appl. No.: 13/099,897 (57) ABSTRACT Pharmaceutical combination containing lipoic acid and (22) Filed: May 3, 2011 hydroxycitric acid as active ingredients. The present inven tion relates to a novel pharmaceutical combination and to the Related U.S. Application Data use thereof for producing a medicament having an antitumor (63) Continuation of application No. PCT/FR2009/ activity. According to the invention, this combination com 052110, filed on Nov. 2, 2009. prises, as active ingredients: lipoic acid or one of the pharma ceutically acceptable salts thereof, and hydroxycitric acid or (30) Foreign Application Priority Data one of the pharmaceutically acceptable salts thereof. Said active ingredients being formulated together or separately for Nov. 3, 2008 (FR) ....................................... O8574.48 a conjugated, simultaneous or separate use. Patent Application Publication Sep. 29, 2011 Sheet 1 of 9 US 2011/023650.6 A1 lipoic acid alone -29 f2 f Niger of ces i{t} v s 6 g i w 4. 6 8 i 2 Concentrations tumoi.i.
    [Show full text]
  • United States Patent Office Patented Nov
    3,539,306 United States Patent Office Patented Nov. 10, 1970 2 properties of quick activity, durable effect and storage 3,539,306 PROCESS FOR THE PREPARATION Stability, and that, therefore, the same can provide an ex OF HYDROTALCITE cellent, ideal antacid. Teruhiko Kumura and Norio Imataki, Takamatsu-shi, Hydrotalcite is known as a mineral having a chemical Katuyuki Hasui, Kagawa-ken, and Takeo Inoue and 5 Structure of the formula Kimiaki Yasutomi, Nagao-machi, Kagawa-ken, Japan, assignors to Kyowa Chemical Industry Co., Ltd., Tokyo, MgAl(OH) 16CO3 4HO O Al2O3 6MgO CO2: 12H2O Japan, a corporation of Japan No Drawing. Filed July 21, 1967, Ser. No. 654,977 which has been naturally produced in only very limited Claims priority, application Japan, July 25, 1966, areas as Norway and Ural. Also a process for the syn 41/48,349; July 17, 1967, 42/45,658 O thesis of hydrotalcite was disclosed, which comprises add Int. C. COf 5/00, 7/00, A61k 27/06 ing Dry Ice or ammonium carbonate to a mixture of U.S. C. 23-315 4 Claims magnesium oxide and y-alumina or the thermal decom position product from of magnesium nitrate and aluminum nitrate, and thereafter maintaining the system at tempera ABSTRACT OF THE DISCLOSURE, tures below 325 C. and under elevated pressures of total A process for the preparation of hydrotalcite which 2,000-20,000 p.s.i. (Roy et al.: American Journal of comprises mixing an alumium component such as alumi Science 251, 350-353 (1953)). However this process is num Salt With a magnesium component such as magnesium obviously unpractical for industrial scale production of Salt in an aqueous medium in the presence of carbonate hydrotalcite, because the reaction system must be main ion at a pH of at least 8 and thereafter recovering the 20 tained under considerably high pressures.
    [Show full text]
  • Philadelphia
    Saturday, April 18th, 2015 PCOS Awareness Symposium 2015 Philadelphia Polycystic Ovary Syndrome: Creating a Treatment Plan Katherine Sherif, MD Professor & Vice Chair, Department of Medicine Director, Jefferson Women’s Primary Care Thomas Jefferson University The Canary in the Coalmine . PCOS seems to accelerate the aging process . It is possible to reverse the aging process . Be scrupulous in your commitment to be healthy Multiple Systems . Reproductive . Endocrinologic . Cardiac . Renal (kidney) . Hepatic (liver) . Brain (mood) . Dermatologic Multiple Signs & Symptoms Irregular periods, Bleeding too much, Bleeding too little, Anxiety, Depression, Eating disorders, Weight gain, Acanthosis nigricans, Skin tags, Follicular keratitis, Hirsutism, Acne, Alopecia, Excess sweating, Seborrheic dermatitis, Hidradenitis supparativa, Fatty liver, High triglycerides, low HDL-cholesterol, Elevated glucose, Infertility, Breastfeeding problems, Poor sleep, Miscarriages, Fatigue, Endometrial cancer Multiple Pathways GnRH pulsatility Theca cell LH Progesterone 17 - OH P testosterone estrone androstenedione & TGranulosa A* Estradiol X Follicle Peripheral conversion A* = aromatase More Pathways! GnRH Insulin pulsatility Theca cell LH Progesterone 17 - OH P testosterone estrone androstenedione testosterone estradiol X ↓ SHBG Free T X Follicle Peripheral conversion The Magic Bullet The oral contraceptive pill . High doses of estrogen (ethinyl estradiol) . Increase SHBG and lower free testosterone* . Improve skin symptoms in most: . Alopecia .
    [Show full text]
  • Disposal of Solid Chemicals in the Normal Trash
    Disposal of Solid Chemicals in the Normal Trash Many solid chemicals can be safety discarded into the normal trash, provided they are in containers that are not broken or cracked and have tightly fitting caps. These chemicals are considered acceptable for ordinary disposal because they display none of the properties of hazardous waste, are of low acute toxicity, and have not been identified as having any chronic toxic effects as summarized in the National Institute of Occupational Safety and Health (NIOSH) “Registry of Toxic Effects of Chemical Substances”. Examples of chemicals acceptable for disposal as regular trash are listed below. To dispose of these chemicals, place the containers in a box lined with a plastic bag, tape the top of the box shut, write “Normal Trash” on the box and then place the box next to the lab trash container. Only solid forms of these chemicals can be disposed in this manner. Any questions about these chemicals or other chemicals that may be disposed of in the normal trash should be directed to the Hazardous Materials Technician (610) 330-5225. Chemicals Generally Acceptable for Disposal as Regular Trash Acacia powder, gum Detergent (most) Methyl salicylate Sodium carbonate arabic Cation exchange resins Methylene blue Sodium chloride Acid, Ascorbic Chromatographic Methyl stearate Sodium citrate Acid, Benzoic absorbents Nutrient agar Sodium dodecyl sulfate Acid, Boric Crystal violet Octacosane (SDS) Acid, Casamind Dextrin Parafin Sodium formate Acid, Citric Dextrose Pepsin Sodium iodide Acid, Lactic Diatomaceous
    [Show full text]
  • Dietary Supplements Compendium Volume 1
    2015 Dietary Supplements Compendium DSC Volume 1 General Notices and Requirements USP–NF General Chapters USP–NF Dietary Supplement Monographs USP–NF Excipient Monographs FCC General Provisions FCC Monographs FCC Identity Standards FCC Appendices Reagents, Indicators, and Solutions Reference Tables DSC217M_DSCVol1_Title_2015-01_V3.indd 1 2/2/15 12:18 PM 2 Notice and Warning Concerning U.S. Patent or Trademark Rights The inclusion in the USP Dietary Supplements Compendium of a monograph on any dietary supplement in respect to which patent or trademark rights may exist shall not be deemed, and is not intended as, a grant of, or authority to exercise, any right or privilege protected by such patent or trademark. All such rights and privileges are vested in the patent or trademark owner, and no other person may exercise the same without express permission, authority, or license secured from such patent or trademark owner. Concerning Use of the USP Dietary Supplements Compendium Attention is called to the fact that USP Dietary Supplements Compendium text is fully copyrighted. Authors and others wishing to use portions of the text should request permission to do so from the Legal Department of the United States Pharmacopeial Convention. Copyright © 2015 The United States Pharmacopeial Convention ISBN: 978-1-936424-41-2 12601 Twinbrook Parkway, Rockville, MD 20852 All rights reserved. DSC Contents iii Contents USP Dietary Supplements Compendium Volume 1 Volume 2 Members . v. Preface . v Mission and Preface . 1 Dietary Supplements Admission Evaluations . 1. General Notices and Requirements . 9 USP Dietary Supplement Verification Program . .205 USP–NF General Chapters . 25 Dietary Supplements Regulatory USP–NF Dietary Supplement Monographs .
    [Show full text]
  • Medications and the Gluten-Free Diet
    Resources for GF Drug Medications and the Information: Gluten-Free Diet - www.glutenfreedrugs.com (Pharmacist controlled site) Updated January 2021 - dailymed.nlm.nih.gov/ Staying gluten-free involves more than just dietary changes.While use of dailymed/ gluten as an ingredient in medications is uncommon, medications must also be evaluated for their gluten content. Many pharmaceuticals have an additional filler called an excipient, used to make a particular dosage form of the drug. These fillers are often made from corn, potato, or tapioca. However, some are derived This educational bulletin has been from wheat or, rarely, barley. If you have doubts about the gluten-free status of a produced by the Gluten Intolerance medication, it is important that you consult with your pharmacist and/or check with Group of North America, a registered the manufacturer of the product. 501(c)3 organization. Learn more about GIG at www.gluten.org. The majority of drug manufacturers do not clearly label their products or packaging with information regarding the gluten content of their drug. Medications GIG is on a mission to make life easier – whether prescription or over-the-counter - are not included in the FDA gluten- for everyone living gluten-free. free labeling regulation which applies to FDA-regulated food products. In late 2017 the FDA issued a draft document on labeling recommendations for medications; as of May 2018 the guidelines were not finalized. If and when This information is for educational purposes only. Consult your such guidelines are finalized, consumers may have easier access to information healthcare team when considering about the gluten content of medications.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Mitochondrial Dysfunction and Chronic Inflammation in Polycystic
    International Journal of Molecular Sciences Review Mitochondrial Dysfunction and Chronic Inflammation in Polycystic Ovary Syndrome Siarhei A. Dabravolski 1,*, Nikita G. Nikiforov 2,3,4, Ali H. Eid 5,6,7, Ludmila V. Nedosugova 8, Antonina V. Starodubova 9,10, Tatyana V. Popkova 11, Evgeny E. Bezsonov 4,12 and Alexander N. Orekhov 4 1 Department of Clinical Diagnostics, Vitebsk State Academy of Veterinary Medicine [UO VGAVM], 7/11 Dovatora Str., 210026 Vitebsk, Belarus 2 Center of Collective Usage, Institute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilova Street, 119334 Moscow, Russia; [email protected] 3 Laboratory of Medical Genetics, Institute of Experimental Cardiology, National Medical Research Center of Cardiology, 121552 Moscow, Russia 4 Laboratory of Cellular and Molecular Pathology of Cardiovascular System, Institute of Human Morphology, 3 Tsyurupa Street, 117418 Moscow, Russia; [email protected] (E.E.B.); [email protected] (A.N.O.) 5 Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha 2713, Qatar; [email protected] 6 Biomedical and Pharmaceutical Research Unit, QU Health, Qatar University, Doha 2713, Qatar 7 Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon 8 Citation: Dabravolski, S.A.; Federal State Autonomous Educational Institution of Higher Education, I. M. Sechenov First Moscow State Nikiforov, N.G.; Eid, A.H.; Medical University (Sechenov University), 8/2 Trubenskaya Street, 119991 Moscow, Russia; [email protected] 9 Federal Research Centre for Nutrition, Biotechnology and Food Safety, 2/14 Ustinsky Passage, Nedosugova, L.V.; Starodubova, A.V.; 109240 Moscow, Russia; [email protected] Popkova, T.V.; Bezsonov, E.E.; 10 Pirogov Russian National Research Medical University, 1 Ostrovitianov Street, 117997 Moscow, Russia Orekhov, A.N.
    [Show full text]